3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
2
Phase 2
2
Phase 1/2
2
Phase NA
1
Phase 3
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
CNS
1
Conditions
Neuroblastoma
7
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Neuroendocrine Tumors
1
Neoplasms
1
Ganglioneuroblastoma
1
Interventions
Everolimus
10
lutetium Lu 177 dotatate
5
Magnetic Resonance Spectroscopy
5
pasireotide
4
Specimen Handling
3
Positron Emission Tomography Computed Tomography
3
Fluorodeoxyglucose F18
3
(177)Lu-DOTA-EB-TATE
3
olaparib
2
amino-acid, glucose, and electrolyte solution
2
Temozolomide
2
Nivolumab
2
FAPI-46
2
veliparib
1
vandetanib
1
trifluridine tipiracil drug combination
1
toripalimab
1
tislelizumab
1
talazoparib
1
surufatinib
1
romidepsin
1
peposertib
1
pembrolizumab
1
pelcitoclax
1
pegfilgrastim
1
fosbretabulin
1
fludarabine phosphate
1
exemestane
1
decitabine and cedazuridine drug combination
1
dactolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neuroendocrine Tumors
×
3-Iodobenzylguanidine
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn